Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-016584
Filing Date
2025-02-07
Accepted
2025-02-07 20:30:20
Documents
2
Period of Report
2025-02-06

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 16706
2 EX-24 tnya-ex24.htm EX-24 6830
  Complete submission text file 0000950170-25-016584.txt   25044
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Issuer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address
Higa Tomohiro (Reporting) CIK: 0002054280 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40656 | Film No.: 25603389